Abstract 6P
Background
PD-1-based immunotherapy is used for first- or second-line therapeutic regimens against NSCLC. Anti-PD-1 immunotherapy resistance occurs in diabetic patients with NSCLC. However, the characteristics of immune cell infiltration in such patients remain unexplored. Thus, we investigated the possible link between diabetes and immune cell infiltration in NSCLC.
Methods
We included patients (n = 437) with NSCLC treated with anti-PD-1 immunotherapy from the Zhejiang University School of Medicine. We analyzed the objective response rate, progression-free survival (PFS), overall survival (OS), T-cell infiltration, and peripheral blood immunological characteristics in diabetic and nondiabetic NSCLC patients. Differences in tumor microenvironment profiles were measured using CyTOF to elucidate the reasons for poor PFS and OS in diabetic NSCLC patients.
Results
Nondiabetic NSCLC patients had longer PFS than diabetic NSCLC patients (11.0 vs 7.0 months). The OS was 24.0 and 17.0 months in nondiabetic and diabetic NSCLC patients, respectively (P = 0.0065). Diabetic NSCLC patients had significantly lower CD8+T cell infiltration than nondiabetic NSCLC patients (P = 0.0227). Similarly, the anti-tumor effect of PD-1 blockade was decreased in diabetic mice with lung cancer. Additionally, compared with nondiabetic NSCLC patients before anti-PD1 treatment, CyTOF analysis showed that diabetic NSCLC patients had significantly more CD161+CD127+CD8+ T cells (P = 0.0071), and this trend continued after anti-PD1 treatment (P = 0.0393). Flow cytometry showed that diabetic NSCLC patients had a significantly higher CD161+CD127+CD8+T/CD8+ T cells ratio than nondiabetic NSCLC patients. Kaplan–Meier survival analysis showed that high levels of CD161+CD127+CD8+ T cells were positively related to the PFS in diabetic NSCLC patients.
Conclusions
We confirmed that diabetes is a risk factor for patients with NSCLC who undergo anti-PD-1 immunotherapy. CD161+CD127+CD8+ T cells in diabetic NSCLC patients serve as a key indicator of poor prognosis. Our findings provide a reference for understanding the characteristics of the tumor microenvironment in diabetic NSCLC patients.
Editorial acknowledgement
Prof. Nong Yang from the Lung Cancer and Gastroenterology Department, Hunan Cancer Hospital, and the Affiliated Tumor Hospital of Xiangya Medical School of Central South University for their technical support. Editage for English language editing.
Legal entity responsible for the study
Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, P. R. China.
Funding
This work was supported by grants from the National Natural Science Foundation of China (No. 81802278), Natural Science Foundation of Zhejiang Province (No.LY23H160020), Medicine Health Technology Plan of Zhejiang Province, China (No. 2022KY150), and General Project of Education Department of Zhejiang Province (Y202043420).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
137P - First-in-human results from a Phase I dose-escalation study of VSV-GP (BI 1831169) in patients with advanced solid tumors
Presenter: Stephane Champiat
Session: Poster Display
138P - Generation of frameshift mutated TGF_R2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV-1/GM-CSF
Presenter: Else Inderberg
Session: Poster Display
139P - Safety and clinical activity of a novel anti-CCR8 antibody (LM-108) as a single agent or in combination with pembrolizumab in patients with advanced solid tumors: Results of phase 1 study
Presenter: Alexander Starodub
Session: Poster Display
140P - Eliciting mAbs targeting MHC-bound peptides with a novel antibody discovery platform
Presenter: Elli Sandberg
Session: Poster Display
141P - An IgE antibody targeting the melanoma-associated Chondroitin Sulfate Proteoglycan 4
Presenter: Lais Cristina Palhares
Session: Poster Display
142P - Identifying novel immunotherapy targets using machine learning and ex vivo validation
Presenter: Marcellus Augustine
Session: Poster Display
143P - Advancing Cancer Immunotherapy via HLA-G Pathway Modulation with UCB4594
Presenter: Ann WHITE
Session: Poster Display
144P - Discovery of CBO421, a first-in-class Drug Fc-Conjugate (DFC), targeting CD73 in Cancer
Presenter: Simon Döhrmann
Session: Poster Display
145P - An Engineered Ligand-Trap Biologic Targeting the CD47 Signaling Pathway for Cancer Treatment with Superb Efficacy and Safety Profiles
Presenter: ZONG SEAN JUO
Session: Poster Display
146P - A Novel Allosteric Oral Immunotherapy Small Molecule Modulates Adenosine 2A Receptor Signaling and Restores Anti-Tumor Immune Responses
Presenter: David Pejoski
Session: Poster Display